Advertisement

Drugs

, Volume 62, Issue 11, pp 1599–1609 | Cite as

Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis

  • Michael T. NurmohamedEmail author
  • Vokko P. van Halm
  • Ben A. C. Dijkmans
Therapy in Practice

Abstract

Several new drugs have become available for the treatment of patients with osteoarthritis and rheumatoid arthritis (RA). These agents include selective cyclooxygenase (COX)-2 inhibitors, leflunomide and anti-tumour necrosis factor (TNF)-α antagonists.

COX-2 inhibitors have a more favourable gastrointestinal adverse effect profile than conventional non-steroidal anti-inflammatory drugs (NSAIDs). However, the COX-2 inhibitors are also associated with hypertension, oedema and congestive heart failure, the well-known adverse effects of conventional NSAIDs. Patients with treated hypertension should be monitored regularly when conventional NSAIDs or COX-2 inhibitors are administered. At present, there is a considerable debate regarding the risk of cardiovascular events with the COX-2 inhibitors. The available literature gives no unequivocal answers. This matter can only be solved by an appropriate trial assessing the cardiovascular risk of these agents.

Patients with RA appear to have an enhanced cardiovascular risk which might be related to an unfavourable lipid profile. Corticosteroids induce hypercholesterolaemia in patients other than those with RA. It was recently shown that total and high-density lipoprotein (HDL) cholesterol were low in patients with RA who had a high disease activity. Contrary to the expectation, combination therapy with prednisolone rapidly improved the atherogenic index (total/HDL cholesterol). Ongoing studies investigating this topic are underway.

It is not known to what extent corticosteroids induce hypertension in patients with RA. Hence, we advocate blood pressure control for these patients.

A small percentage of patients with RA develop hypertension when taking leflunomide, and no other serious cardiovascular adverse effects have been reported in the literature. Blood pressure monitoring is recommended especially in the first months of treatment.

TNFα antagonists are contraindicated in patients with RA who have congestive heart failure. No specific cardiovascular adverse effects have been reported with the use of these agents in the non-cardiovascular compromised patient. TNFα antagonists are the most powerful anti-inflammatory drugs presently available. As inflammation plays an important role in RA as well as in cardiovascular disease and, in view of the increased cardiovascular risk in RA, it is tempting to expect that suppression of inflammation ultimately will lower the cardiovascular morbidity and mortality in patients with RA.

Keywords

Rheumatoid Arthritis Infliximab Etanercept Celecoxib Naproxen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used in the preparation of this manuscript, and the authors have no potential conflicts of interest.

References

  1. 1.
    Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995; 38: 1134–41PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15CrossRefGoogle Scholar
  3. 3.
    Felson DT. The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments. Arthritis Rheum 2001; 44: 1477–80PubMedCrossRefGoogle Scholar
  4. 4.
    Pincus T, Koch GG, Sokka T, et al. Arandomised, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 1587–98PubMedCrossRefGoogle Scholar
  5. 5.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRefGoogle Scholar
  6. 6.
    Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazol with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719–26PubMedCrossRefGoogle Scholar
  7. 7.
    Hawkey CJ, Karrasch JA, Szczeepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727–34PubMedCrossRefGoogle Scholar
  8. 8.
    Lems WF, Dijkmans BAC. Rheumatoid arthritis: clinical aspects and its variants. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. New York: Oxford University Press, 2000: 213–225Google Scholar
  9. 9.
    American College of Rheumatology ad hoc Committees on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22CrossRefGoogle Scholar
  10. 10.
    Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 30–5PubMedCrossRefGoogle Scholar
  11. 11.
    Rau R. Methotrexate. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford (NY): Oxford University Press, 2000: 337–50Google Scholar
  12. 12.
    Boers M. Rheumatoid arthritis: treatment of early disease. Rheum Dis Clin North Am 2001; 27: 405–14PubMedCrossRefGoogle Scholar
  13. 13.
    Kirwan JR. Systemic low-dose glucocorticoid in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 389–403PubMedCrossRefGoogle Scholar
  14. 14.
    Lee DL, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11PubMedCrossRefGoogle Scholar
  15. 15.
    Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naprxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109–20PubMedGoogle Scholar
  16. 16.
    Thun MJ. Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology 2000; 11: 371–4PubMedCrossRefGoogle Scholar
  17. 17.
    Lichtenstein DR, Wolfe MM. Cox-2-selective NSAIDs: new and improved? JAMA 2000; 284: 1297–9PubMedCrossRefGoogle Scholar
  18. 18.
    Schonbeck U, Sukhova GK Graber P, at al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281–91PubMedCrossRefGoogle Scholar
  19. 19.
    Topper JN, Cai J, Falb D, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical: cyclooxygenase-2, manganese Superoxide dismutase, and endothelial nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996; 93: 10417–22PubMedCrossRefGoogle Scholar
  20. 20.
    Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–9PubMedCrossRefGoogle Scholar
  21. 21.
    Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase- 2. New Engl J Med 2001; 345: 433–42PubMedCrossRefGoogle Scholar
  22. 22.
    Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001; 110(3A): 28S–32SPubMedCrossRefGoogle Scholar
  23. 23.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  24. 24.
    Silverstein FE, Percival MD, Brideau C, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247–5PubMedCrossRefGoogle Scholar
  25. 25.
    Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and nonaspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382–7PubMedCrossRefGoogle Scholar
  26. 26.
    Patrono C, Collier B, Dalen JE, et al. Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63SCrossRefGoogle Scholar
  27. 27.
    Josefson D. FDA warns Merck over its promotion of rofecoxib. BMJ 2001; 323: 767PubMedCrossRefGoogle Scholar
  28. 28.
    Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222–3PubMedCrossRefGoogle Scholar
  29. 29.
    Nurmohamed MT, Dijkmans BAC. Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate. Ann Rheum Dis 2001; 60: 905–7PubMedCrossRefGoogle Scholar
  30. 30.
    Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63–74PubMedCrossRefGoogle Scholar
  31. 31.
    Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 1998; 20: 376–87PubMedCrossRefGoogle Scholar
  32. 32.
    De Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension: the risk in perspective. Drugs 1996; 51: 179–87PubMedCrossRefGoogle Scholar
  33. 33.
    Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2—specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8(2): 85–95PubMedCrossRefGoogle Scholar
  34. 34.
    Schnitzer TJ. Cyclooxygenase-2-specific inhibitors: are they safe? Am J Med 2001; HO(IA): 46S-49SGoogle Scholar
  35. 35.
    Geba GP, Weaver AL, Schnitzer TJ, et al. A clinical trial comparing rofecoxib to celcoxib and acetaminophen in the treatment of osteoarthritis (OA): early efficacy results [abstract]. Ann Rheum Dis 2000; 59 Suppl. 1: 291Google Scholar
  36. 36.
    Feenstra J, Grobbee DE, Remme WJ, et al. Drug induced heart failure. J Am Coll Cardiol 1999; 33: 1152–62PubMedCrossRefGoogle Scholar
  37. 37.
    BunningRD, Barth WF. Sulindac: a potential renal-sparing nonsteroidal anti-inflammatory drug. JAMA 1982; 248: 2864–7CrossRefGoogle Scholar
  38. 38.
    Aronoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 25–31Google Scholar
  39. 39.
    Furst DE. Are there differences among nonsteroidal anti-inflammatory drugs?.: comparing acetylated salicylates, non-acetylated salicylates and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 1–9PubMedCrossRefGoogle Scholar
  40. 40.
    Skeith KJ, Wright M, Davis P. Differences in NS AID tolerability profiles: fact or fiction? Drug Saf 1994; 10: 183–95PubMedCrossRefGoogle Scholar
  41. 41.
    Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Int Med 2000; 160: 777–84CrossRefGoogle Scholar
  42. 42.
    Everts B, Währborg P, Hedner T. Cox-2-specific inhibitors: the emergence of a new class analgesic and anti-inflammatory drugs. Clin Rheumatol 2000; 19: 313–43CrossRefGoogle Scholar
  43. 43.
    Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase inhibition in normotensive salt-depleted subjects. Clin Pharmacol Exper Ther 1999; 289: 735–41Google Scholar
  44. 44.
    Swan SK, Rudy DW, Lasseter KC. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomised controlled trial. Ann Intern Med 2000; 133: 1–9PubMedGoogle Scholar
  45. 45.
    Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115–23PubMedCrossRefGoogle Scholar
  46. 46.
    Saag KG, Criswell LA, Sems KM, et al. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996; 39: 1818–25PubMedCrossRefGoogle Scholar
  47. 47.
    Becker D, Chamberlain B, Swank R, et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant patients. Am J Med 1988; 85: 632–8PubMedCrossRefGoogle Scholar
  48. 48.
    Lippuner K, Casez JP, Horber FF, et al. Effects of deflazacort versus prednisone on bone mass, body compositioin, and lipid profile: a randomised double blind study in kidney transplant patients. J Clin Endocrinol Metab 1998; 83: 3795–802PubMedCrossRefGoogle Scholar
  49. 49.
    Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505–11PubMedGoogle Scholar
  50. 50.
    Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension. Clin Sci (Colch) 1981; 61 Suppl. 7: 318S–3SGoogle Scholar
  51. 51.
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolon, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18PubMedCrossRefGoogle Scholar
  52. 52.
    Svenson KLG, Lithell H, Hällgren R, et al. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides I: relativity to inflammatory activity. Arch Intern Med 1987; 147: 1912–6PubMedCrossRefGoogle Scholar
  53. 53.
    Svenson KLG, Lithell H, Hällgren R, et al. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory artrtitides II: effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147: 1917–20PubMedCrossRefGoogle Scholar
  54. 54.
    Boers M, Nurmohamed MT, Doelman CJ, et al. Cortocosteroids and cholesterol levels in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl. 9: S53CrossRefGoogle Scholar
  55. 55.
    Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997; 24: 445–51PubMedGoogle Scholar
  56. 56.
    Banks M, Flint J, Bacon PA, et al. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease [abstract]. Arthritis Rheum 2000; 43 Suppl. 9: S385Google Scholar
  57. 57.
    Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259–66PubMedCrossRefGoogle Scholar
  58. 58.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542–50PubMedCrossRefGoogle Scholar
  59. 59.
    Smolen JS, Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology 2000; 39 Suppl. 1: 48–56PubMedCrossRefGoogle Scholar
  60. 60.
    Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthrtitis with leflunomide: two year follow up of a double blind placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913–23PubMedCrossRefGoogle Scholar
  61. 61.
    Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomised, controlled trial of active rheumatoid arthritis compared with methotrexate: utilization of leflunomide in the treatment of rheumatoid arthrititis trial investigator group. Arthritis Rheum 2001; 44: 1984–92PubMedCrossRefGoogle Scholar
  62. 62.
    Van Pelt A, van Schaardenburg DJ, Bultink IEM, et al. High discontinuation rate of treatment with leflunomide in daily practice [abstract]. Arthritis Rheum 2001; 44 Suppl. 9: S143Google Scholar
  63. 63.
    Francis GS. TNF-α and heart failure: the difference between proof of principle and hypothesis testing. Circulation 1999; 99: 3213–4PubMedCrossRefGoogle Scholar
  64. 64.
    Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224–6PubMedCrossRefGoogle Scholar
  65. 65.
    Bozkurt B, Torre-Amioni G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044–7PubMedCrossRefGoogle Scholar
  66. 66.
    Louis A, Cleland JFG, Crabbe, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Eur J Heart Fail 2001; 3: 381–7PubMedCrossRefGoogle Scholar
  67. 67.
    Food and Drug Administration. Medwatch 2001; Available from URL: http://www.fda.gov/medwatch/safety/2001/remicade_deardoc.pdf. [Accessed 2002 Feb 12]
  68. 68.
    Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657–62PubMedCrossRefGoogle Scholar
  69. 69.
    Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 2001; 104: 2280–8PubMedCrossRefGoogle Scholar
  70. 70.
    Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118–23PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Michael T. Nurmohamed
    • 1
    • 2
    Email author
  • Vokko P. van Halm
    • 1
    • 2
  • Ben A. C. Dijkmans
    • 1
    • 2
    • 3
  1. 1.Department of RheumatologyVU University Medical CentreAmsterdamThe Netherlands
  2. 2.Jan van Breemen InstituteAmsterdamThe Netherlands
  3. 3.Slotervaart HospitalAmsterdamThe Netherlands

Personalised recommendations